The Library
Geography influences susceptibility to SARS-CoV-2 serological response in patients with inflammatory bowel disease : multinational analysis from the ICARUS-IBD Consortium
Tools
(2023) Geography influences susceptibility to SARS-CoV-2 serological response in patients with inflammatory bowel disease : multinational analysis from the ICARUS-IBD Consortium. Inflammatory Bowel Diseases, 29 (11). pp. 1693-1705. doi:10.1093/ibd/izad097 ISSN 1078-0998.
PDF
WRAP-geography-influences-susceptibility-SARS-CoV-2-serological-response-patients-inflammatory-bowel-disease-Thompson-2023.pdf - Accepted Version Embargoed item. Restricted access to Repository staff only until 24 June 2024. Contact author directly, specifying your specific needs. - Requires a PDF viewer. Download (2076Kb) |
Official URL: https://doi.org/10.1093/ibd/izad097
Abstract
Background:
Beyond systematic reviews and meta-analyses, there have been no direct studies of serological response to COVID-19 in patients with inflammatory bowel disease (IBD) across continents. In particular, there has been limited data from Asia, with no data reported from India. The ICARUS-IBD (International study of COVID-19 Antibody Response Under Sustained immunosuppression in IBD) consortium assessed serological response to SARS-CoV-2 in patients with IBD in North America, Europe, and Asia.
Methods:
The ICARUS-IBD study is a multicenter observational cohort study spanning sites in 7 countries. We report seroprevalence data from 2303 patients with IBD before COVID-19 vaccination between May 2020 and November 2021. SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies were analyzed.
Results:
The highest and lowest SARS-CoV-2 anti-spike seropositivity rates were found in Asia (81.2% in Chandigarh and 57.9% in Delhi, India; and 0% in Hong Kong). By multivariable analysis, country (India: odds ratio [OR], 18.01; 95% confidence interval [CI], 12.03-26.95; P < .0001; United Kingdom: OR, 2.43; 95% CI, 1.58-3.72; P < .0001; United States: OR, 2.21; 95% CI, 1.27-3.85; P = .005), male sex (OR, 1.46; 95% CI, 1.07-1.99; P = .016), and diabetes (OR, 2.37; 95% CI, 1.04-5.46; P = .039) conferred higher seropositivity rates. Biological therapies associated with lower seroprevalence (OR, 0.22; 95% CI, 0.15-0.33; P < .0001). Multiple linear regression showed associations between anti-spike and anti-nucleocapsid titers with medications (P < .0001) but not with country (P = .3841).
Conclusions:
While the effects of medications on anti-SARS-CoV-2 antibody titers in patients with IBD were consistent across sites, geographical location conferred the highest risk of susceptibility to serologically detectable SARS-CoV-2 infection. Over half of IBD patients in India were seropositive prior to vaccination. These insights can help to inform shielding advice, therapeutic choices, and vaccine strategies in IBD patients for COVID-19 and future viral challenges.
Item Type: | Journal Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Subjects: | Q Science > QR Microbiology Q Science > QR Microbiology > QR180 Immunology Q Science > QR Microbiology > QR355 Virology R Medicine > RA Public aspects of medicine R Medicine > RB Pathology |
||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Microbiology & Infection |
||||||||
Library of Congress Subject Headings (LCSH): | COVID-19 (Disease) -- Epidemiology, Inflammatory bowel diseases, Vaccines, Viral vaccines -- Research, Viral vaccines -- Development | ||||||||
Journal or Publication Title: | Inflammatory Bowel Diseases | ||||||||
Publisher: | John Wiley & Sons, Inc. | ||||||||
ISSN: | 1078-0998 | ||||||||
Official Date: | November 2023 | ||||||||
Dates: |
|
||||||||
Volume: | 29 | ||||||||
Number: | 11 | ||||||||
Page Range: | pp. 1693-1705 | ||||||||
DOI: | 10.1093/ibd/izad097 | ||||||||
Status: | Peer Reviewed | ||||||||
Publication Status: | Published | ||||||||
Re-use Statement: | This is the peer reviewed version of the following article: Serre-Yu Wong, MD, PhD and others, Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium, Inflammatory Bowel Diseases, 2023;, izad097, which has been published in final form at https://doi.org/10.1093/ibd/izad097. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. | ||||||||
Access rights to Published version: | Restricted or Subscription Access | ||||||||
Date of first compliant deposit: | 19 July 2023 | ||||||||
Funder: | The Leona M. and Harry B. Helmsley Charitable Trust | ||||||||
Grant number: | 2107-04731 | ||||||||
Contributors: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |